Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX)

85.00
Delayed Data
As of Sep 29
 -3.84 / -4.32%
Today’s Change
75.90
Today|||52-Week Range
134.71
-32.45%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$22.0B

Company Description

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Contact Information

Vertex Pharmaceuticals, Inc.
50 Northern Avenue
Boston Massachusetts 02210
P:(617) 341-6100
Investor Relations:
(617) 444-6108

Employees

Shareholders

Mutual fund holders69.18%
Other institutional29.10%
Individual stakeholders1.15%

Top Executives

Jeffrey M. LeidenChairman, President & Chief Executive Officer
Simon BedsonSVP & GM-International Commercial Operations
Ian F. SmithChief Financial Officer & Executive Vice President
David Matthew AltshulerChief Scientific Officer & EVP-Global Research
Jeffrey A. ChodakewitzChief Medical Officer & Executive Vice President